ReviewJournal of arrhythmia2026
Clinical Advantages and Pitfalls of Pulsed Field Ablation: How to Prevent ALH Syndrome.
Review in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter ablation for tachyarrhythmias was first introduced in the early 1980s using direct-current (DC) energy. Following the clinical introduction of radiofrequency (RF) ablation in the late 1980s, thermal ablation technologies became the foundation of catheter ablation because of their superior controllability, efficacy, and safety. In 2014, Wittkampf developed a DC-energy-delivery catheter system preventing electrical arcing, thereby initiating a modern "revival of DC-ablation" based on catheter ablation using electroporation. Subsequent development of high-voltage, short-duration pulse-train delivery led to the emergence of pulsed field ablation (PFA). Exposure of myocytes to high-voltage electric fields induces reversible electroporation through nanoscale pore formation within the lipid bilayer, whereas higher electric-field delivery produces irreversible electroporation, resulting in permanent membrane disruption, apoptosis, and durable lesion formation. PFA is regarded as a predominantly nonthermal and potentially tissue-selective ablation modality. Nevertheless, clinical trials of pulmonary vein isolation for atrial fibrillation have demonstrated that PFA is noninferior to conventional thermal ablation strategies, although clear superiority-other than shorter procedural times-has not yet been established. Importantly, recent studies suggest that electrode-tissue contact remains a critical determinant of durable lesion formation. Accumulating evidence indicates that PFA is associated with new complications not commonly observed with thermal ablation, including acute kidney injury, stroke, coronary vasospasm, myocardial ischemia, ventricular fibrillation, and sudden cardiac death. Although the mechanisms remain incompletely understood, hemolysis-related injury induced by high-voltage pulse delivery may represent an important contributing mechanism. Development of PFA systems capable of real-time prediction of irreversible lesion size may be essential for optimizing both procedural efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.